Schumakov National Medical Research Center, Moscow, Russia.
Department of Cardiothoracic Surgery, University Hospital of Cologne, Cologne, Germany.
Clin Transplant. 2021 Jul;35(7):e14341. doi: 10.1111/ctr.14341. Epub 2021 May 25.
Heart transplantation (HTx) remains the treatment of choice for patients with end-stage advanced heart failure. In 2016, the Shumakov National Medical Research Center commenced performing HTx from donors with abnormal left ventricular systolic function (LVEF < 40%). The aim of this study was to evaluate early and late outcomes of recipients after HTx from donors with abnormal LV systolic function.
Four hundred eighty seven patients underwent HTx in our institution from January 2016 to December 2018. 27 (5.5%) patients were transplanted using cardiac allografts from donors with LVEF <40%.
A total of 47 donors with LVEF <40% were evaluated for potential donation. Most heart donors revealed a left ventricular ejection fraction ranging between 30% and 40%. Twenty-five recipients required urgent HTx. Four recipients presented with early allograft dysfunction. All surviving recipients demonstrated early (85.2%) or delayed (14.8%) recovery of systolic function (LVEF > 60%).
The use of dysfunctional donor hearts with impaired LV systolic function may be a realistic approach for expanding the donor pool. However, organs from such donors should be used for recipient cohorts requiring an urgent HTx, particularly for those with pretransplant mechanical circulatory support allowing for hemodynamic support in cases of early graft dysfunction in the post-transplant period.
心脏移植(HTx)仍然是晚期心力衰竭患者的首选治疗方法。2016 年,舒马科夫国家医学研究中心开始从左心室收缩功能异常(LVEF<40%)的供体中进行 HTx。本研究旨在评估从左心室收缩功能异常的供体中接受 HTx 的受者的早期和晚期结局。
本机构于 2016 年 1 月至 2018 年 12 月期间对 487 例患者进行了 HTx。27 例(5.5%)患者使用 LVEF<40%的供体心脏进行了心脏移植。
共评估了 47 名 LVEF<40%的潜在供体进行捐赠。大多数供体心脏的左心室射血分数在 30%到 40%之间。25 例受者需要紧急 HTx。4 例受者出现早期移植物功能障碍。所有存活的受者均表现出早期(85.2%)或延迟(14.8%)的收缩功能恢复(LVEF>60%)。
使用功能失调的供体心脏,其左心室收缩功能受损,可能是扩大供体库的一种现实方法。然而,应将此类供体的器官用于需要紧急 HTx 的受者群体,特别是那些在移植前有机械循环支持的患者,以在移植后早期移植物功能障碍的情况下提供血流动力学支持。